SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Alexion Pharmaceuticals logo
2 weeks ago

Director, US Marketing, NF1 PN

Alexion Pharmaceuticals

Boston, MA (Unknown)$194K/yr – $291K/yr
Alexion Pharmaceuticals logo
2 weeks ago

Senior Manager, US Marketing, NMOSD

Alexion Pharmaceuticals

Boston, MA (Unknown)$116K/yr – $152K/yr
Alexion Pharmaceuticals logo
2 weeks ago

Senior Manager, US Marketing, Rare Hematology

Alexion Pharmaceuticals

Boston, MA (Unknown)$116K/yr – $174K/yr
Alexion Pharmaceuticals logo
3 weeks ago

Thought Leader Liaison, US Neurology (Ohio Region)

Alexion Pharmaceuticals

Cleveland, OH (Unknown)$174K/yr – $261K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Alexion Pharmaceuticals logo

Director, US Marketing, NF1 PN

Alexion Pharmaceuticals

Boston, MA (Unknown)

$194K/yr - $291K/yrIn-houseDirector/executive10+ years exp.
2 weeks ago
Alexion Pharmaceuticals logo

Senior Manager, US Marketing, NMOSD

Alexion Pharmaceuticals

Boston, MA (Unknown)

$116K/yr - $152K/yrIn-houseSenior level
2 weeks ago
Alexion Pharmaceuticals logo

Senior Manager, US Marketing, Rare Hematology

Alexion Pharmaceuticals

Boston, MA (Unknown)

$116K/yr - $174K/yrIn-houseSenior level3+ years exp.
2 weeks ago
Alexion Pharmaceuticals logo

Thought Leader Liaison, US Neurology (Ohio Region)

Alexion Pharmaceuticals

Cleveland, OH (Unknown)

$174K/yr - $261K/yrIn-houseSenior level7+ years exp.
3 weeks ago
Alexion Pharmaceuticals logo
Alexion Pharmaceuticals

Director, US Marketing, NF1 PN

Boston, MA (Unknown)

$194K/yr – $291K/yrDirector/Executive10+ years exp

Posted 2 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the HCP strategy for the NF1 PN US business, translating insights into targeted tactics and leading cross-functional execution across analytics, planning, and communications.

  • Owns brand strategy and executive updates for senior leadership.
  • Partners with analytics and cross-functional teams to inform targeting and budgeting.
  • Drives performance metrics and compliant growth across channels.

Job Description

Responsibilities

  • Brand Strategy Leadership: Own the HCP strategy for the NF1 PN US business, creating a clear plan that differentiates Koselugo and guides field and non-personal promotion to drive appropriate use.
  • Customer Insight Generation: Build a deep, nuanced understanding of HCP and patient needs through research, advisory boards, and sustained KOL engagement; translate findings into targeted, testable tactics.
  • Performance Management: Establish critical metrics for personal and non-personal channels, track progress weekly and monthly, and adjust programs to improve reach, quality of engagement, and treatment adoption.
  • Cross-Functional Leadership: Partner closely with Sales, Training, Medical, Regulatory, Legal, Compliance, Patient Services, and the Promotional Review Committee to align strategy, accelerate execution, and ensure all materials meet the highest standards.
  • People Leadership: Serve as day-to-day manager for the Associate Director of HCP Marketing (dotted line), providing clear priorities, coaching, and feedback to elevate team performance.
  • Media Strategy and Measurement: Lead strategic oversight of the HCP media plan; optimize channel mix, creative rotation, and spend based on impact, efficiency, and brand objectives.
  • Analytics Partnership: Collaborate with commercial analytics and insights teams to assess market dynamics, identify opportunity segments, quantify barriers, and design primary and secondary research that sharpens targeting and messaging.
  • Annual Planning and Budgeting: Drive annual brand planning, connecting short- and long-term priorities to a resourced tactical plan and budget that deliver sustainable, compliant growth.
  • Executive Communication: Build streamlined, persuasive updates for senior commercial and medical leadership through monthly business reviews and quarterly reviews; highlight learnings, decisions, and next steps.
  • Agency and Resource Management: Direct the brand agency of record and other partners, ensuring on-brief delivery, speed, and value; manage budgets with rigor and transparency.

Requirements

  • Bachelor's degree
  • 10+ years of professional experience; prefer marketing, sales, agency, or health care experience
  • Track record of developing and implementing marketing strategies and tactics that have delivered strong commercial results in competitive environments
  • Proven leadership skills and the ability to collaborate in a matrix environment
  • Track record that demonstrates the ability to build high performing teams and support individuals in their professional development
  • Strong ability to manage multiple projects across functional areas, and work independently when appropriate, in teams and as a sub-team lead
  • The duties of this role are generally conducted in an office environment. As is typical of an office-based role, employees must be able, with or without an accommodation to: use a computer; engage in communications via phone, video, and electronic messaging; problem solve; engage in complex and non-linear thought, analysis, and dialogue; collaborate with others; maintain general availability during standard business hours

Preferred

  • Advanced degree, MBA
  • Strong scientific orientation and background
  • Rare disease/high-value biologics experience
Alexion Pharmaceuticals logo

Alexion Pharmaceuticals

3.9 Glassdoor

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease. A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally. GL/NP/0116GL/NP/0095 Community Guidelines: https://bit.ly/39x9gqy

Founded in 1992
New Boston, Massachusetts, USA
5.1K employees (133 in marketing)
www.alexion.com
72% recommend to a friend
73% CEO approval

Traffic Signals

Monthly Visitors
81.8K
Traffic Source Mix
Search
48.2%
Direct
37.5%
Referral
7.7%
Social
5.1%
Paid
1.5%

Headcount Trend

Current headcount: ~5.1K

Marketing Team

Marketing Team Size
133 (3% of company)
Marketing Roles Posted (Last 30 Days)
4

Funding

Total Funding
$5.8M
Last Raise
$5.8M
Post IPO Equity, 27 years ago

Funding History

  • Feb 1999
    Post IPO Equity • $5.8M

Recent News

Novartis Says Alexion's 'Block The Cause' Ads Are False
Oct 21, 2025 • Law360
Koselugo recommended for EU approval
Sep 22, 2025 • News Powered by Cision
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
Sep 19, 2025 • Business Wire
Alexion, AstraZeneca Rare Disease welcomes Irish partners to global operations hub in Cork
Sep 19, 2025 • IDA Ireland
AstraZeneca says Ultomiris shows 3 years relapse-free in NMOSD
Sep 19, 2025 • MarketScreener
Lysosomal Storage Disorders (LSDs) Market Set to Soar: Key Players Drive Innovative Treatments in 2025-2033
Sep 18, 2025 • EIN Presswire
Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
Sep 10, 2025 • PharmiWeb
Global Chronic Idiopathic Urticaria Treatment Market Set for Significant Growth Through 2034
Sep 10, 2025 • EIN Presswire
Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
Sep 10, 2025 • PR Newswire
AstraZeneca launches rare blood, kidney disease drug Eculizumab in India
Sep 9, 2025 • ET Pharma
Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Grifols, Kedrion Biopharma, Octapharma, AstraZeneca's Alexion, Argenx, Horizon Therapeutics, and Biogen Lead Innovations - ResearchAndMarkets.com
Aug 20, 2025 • The AI Journal
Stuttering Market Research Report 2025-2035 | Digital Health Tools and Personalized Medicine Transforming Stuttering Treatment - ResearchAndMarkets.com
Aug 20, 2025 • Business Wire
Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials
Aug 12, 2025 • Quiver Quantitative
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Aug 12, 2025 • Monopar Therapeutics Inc.
Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035
Aug 11, 2025 • Research and Markets
Stuttering Market Research Report 2025-2035 | AstraZeneca, via Alexion, Leads with Strensiq as the First Approved Enzyme Replacement Therapy
Aug 11, 2025 • Research and Markets
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 | Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9
Aug 8, 2025 • Research and Markets
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (g
Aug 7, 2025 • Yahoo Finance
Xencor Reports Second Quarter 2025 Financial Results
Aug 7, 2025 • BioSpace
Enzyme Replacement Therapy Market to Hit USD 21.70 Billion by 2032 | Growing at 8.59% CAGR - SNS Insider
Aug 4, 2025 • SNS Insider pvt ltd
Skeletal Dysplasia Market Growth, Analysis of Key Players, Trends, Drivers
Jul 30, 2025 • PharmiWeb
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial
Jul 24, 2025 • BioPharma Dive
AZ boasts phase 3 win for self-administered gMG drug
Jul 24, 2025 • pharmaphorum
AstraZeneca’s anselamimab treatment fails to meet main trial goal; shares slip
Jul 16, 2025 • Investing.com
Hypophosphatasia Market Epidemiology Report 2025-2035: Pipeline Therapies, Drugs Sales, and Regional Outlook
Jul 14, 2025 • EIN Presswire
JCR’s third deal with Alexion gives rights to AAV capsids
Jul 9, 2025 • BioWorld MedTech
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
Jul 9, 2025 • BioSpace
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
Jul 8, 2025 • Business Wire
In-Depth Analysis Of The Global Familial Amyloid Polyneuropathy FAP market: Key Drivers And Forecast 2025-2034
Jul 3, 2025 • EIN Presswire
Leading Driver In The Lysosomal Enzyme Market 2025: Rising Healthcare Expenditure Fuels Growth In Therapy (ERT) Market
Jul 1, 2025 • EIN Presswire
Paroxysmal Nocturnal Hemoglobinuria Market Set for Robust Growth During the Forecast Period (2025–2034) Owing to the Advancements in Complement Inhibitor Therapies | DelveInsight
Jul 1, 2025 • DelveInsight Business Research LLP
Mid-Size Pharmaceuticals Market Analysis 2025 – Insights For Long-Term Investment & Planning
Jun 30, 2025 • EIN Presswire
Accelerating Plasmid Construct Development with Smart Bioreactors, Upcoming Webinar Hosted by Xtalks
Jun 23, 2025 • PRWeb
Global Autoimmune Hemolytic Anemia Treatment Market Growth: To Reach $1.99 Billion by 2029 with an Impressive 8.9% CAGR
Jun 13, 2025 • EIN Presswire
Alexion Owes Another $181M for Lack of Commercially Reasonable Efforts in Milestone Earnout Case, Chancery Rules
Jun 12, 2025 • Law.com
AstraZeneca takes $181M hit in Syntimmune shareholder lawsuit on top of previous $130M award
Jun 12, 2025 • FiercePharma
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1)
Jun 11, 2025 • bloomberglaw.com
Metastatic Prostate Cancer Market Research 2025-2035: Targeted Therapies on the Rise - The Role of PSMA-Targeted Treatments in Improving Patient Outcomes
Jun 10, 2025 • Research and Markets
Common Technical Document (CTD) and Clinical Overview Guideline Course: Creating Effective Marketing Authorisation Applications (ONLINE EVENT: June 18-19, 2025) - ResearchAndMarkets.com
Jun 2, 2025 • Business Wire
Amgen And Samsung Soliris Biosimilars Skirt UK Infringement On Claim Construction
May 22, 2025 • insights.citeline.com
Federal Court upholds Alexion patent, blocks Amgen biosimilar launch until 2027
May 15, 2025 • Law360 Canada
Global Neuromyelitis Optica Spectrum Disorder Market Forecast To Reach $3.52 Billion By 2029 With 8.4%Annual Growth
May 14, 2025 • EIN Presswire
Methylmalonic Acidemia (MMA) Market Report 2025: Size, Trends, And Growth Insights For Global Expansion
May 13, 2025 • EIN Presswire
Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025 by Company A-Z, Therapy Focus and Technology Type
May 9, 2025 • Research and Markets
American Kidney Fund’s Kidney Action Summit Brings AKF Ambassadors to Capitol Hill to Urge Support of Legislation to Protect Living Donors and Commitment to Protect Medicaid
May 7, 2025 • American Kidney Fund
American Kidney Fund’s Kidney Action Summit Brings AKF Ambassadors to Capitol Hill to Urge Support of Legislation to Protect Living Donors and Commitment to Protect Medicaid
May 7, 2025 • Morningstar.com
Global Generalized Myasthenia Gravis (GMG) Management Mar...
May 2, 2025 • PharmiWeb
Global Marburg Virus Disease Therapeutics Market to Reach...
Apr 30, 2025 • PharmiWeb
Sickle Cell Disease Pipeline Insight 2025: Analysis of 40+ Companies and 50+ Pipeline Drugs in the Sickle Cell Disease Pipeline Landscape
Apr 29, 2025 • Research and Markets
American Kidney Fund Announces 2025 Class of Corporate Members Providing Support in the Fight Against Kidney Disease
Apr 24, 2025 • American Kidney Fund
Myasthenia Gravis Treatment Market anticipated to reach US$2.785 billion by 2030 at a CAGR of 7.14%
Apr 24, 2025 • EIN Presswire
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris
Apr 17, 2025 • Reuters
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris
Apr 17, 2025 • Reuters
AstraZeneca Unit Hit With Antitrust Suit Over Soliris
Apr 17, 2025 • Law360
AstraZeneca's Alexion accused of extending Soliris monopoly through sham patents in new suit
Apr 17, 2025 • Fierce Pharma
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly
Apr 17, 2025 • bloomberglaw.com
The Optic Neuropathy Management Global Market Report 2025: Detailed Insights And Data About The Growing Market.
Mar 27, 2025 • EIN Presswire
Glomerulonephritis Global Market Report 2025: A Latest Comprehensive Analysis Of Industry Size, Drivers, Key Players
Mar 25, 2025 • EIN Presswire
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million by 2035 with Rising Demand for Orphan Drugs – Exclusive Report by Transparency Market Research, Inc.
Mar 18, 2025 • GlobeNewswire News Room
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
Mar 18, 2025 • Morningstar, Inc.
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
Mar 17, 2025 • PharmiWeb.com
Misguided antitrust policies jeopardize Maryland life sciences industry
Mar 7, 2025 • Maryland Daily Record
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet Therapeutics SAS, Ultragenyx Pharmaceutical and Nobelpharma
Mar 7, 2025 • GlobeNewswire News Room
Soliris (Eculizumab) Market Research Report Forecast to 2033
Feb 28, 2025 • PharmiWeb.com
New Interactive Storybook Aims to Educate Children with Rare Kidney Disease into a World of Adventure and Understanding
Feb 12, 2025 • Business Wire
Alexion and DHL Express Lead with 100% Transition to Sustainable Aviation Fuel in Europe
Feb 12, 2025 • EuropaWire
AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug
Feb 6, 2025 • Fierce Biotech
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexif
Dec 18, 2024 • PR Newswire Canada
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Dec 12, 2024 • PharmaVoice
How Alexion markets a rare disease drug by ‘starting with the end in mind’
Dec 3, 2024 • PharmaVoice
Dosage and administration of anti-C5 antibodies for treatment of atypical …
Nov 22, 2024 • Google Patent
KOMET Phase III trial met primary endpoint
Nov 12, 2024 • News Powered by Cision
Two former Alexion leaders fight through a tough market to sustain a rare disease biotech
Nov 5, 2024 • BioPharma Dive
Lyophilized formulations for factor Xa antidote
Sep 13, 2024 • Google Patent
Anti-c5 antibodies having improved pharmacokinetics
Jul 16, 2024 • Google Patent
Pediatric dosage and administration of anti-c5 antibodies for treatment of …
Apr 30, 2024 • Google Patent
Systems and methods for monitoring quality of life (qol) features in pnh …
Apr 28, 2024 • Google Patent
FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
Apr 15, 2024 • GlobeNewswire
Alexion Canada Appoints Karen Heim as New General Manager
Apr 1, 2024 • Yahoo Finance Canada
Alexion Pharmaceuticals patents complement C1s subcomponent inhibitors
Mar 18, 2024 • http://www.zdnet.com/
Methods and compositions for treating complement-associated disorders
Mar 15, 2024 • Google Patent
Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key ...
Jan 24, 2024 • PR Newswire
Boston Retirement System, et al. v. Alexion Pharmaceuticals, Inc., et al.
Oct 30, 2023 • globallegalchronicle.com
Alexion Pharmaceuticals describes new C1s inhibitors
Oct 19, 2023 • http://www.zdnet.com/
Dosage and administration of anti-c5 antibodies for preventing or minimizing …
Sep 26, 2023 • Google Patent
Diagnostic and prognostic biomarker profiles in patients with hematopoietic …
Sep 5, 2023 • Google Patent
As markets crash, Moderna shares see gains
Jan 1, 1970 • Fortune
Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance
Jan 1, 1970 • Yahoo! News
US stock indices snap 3-week gaining streak; Asia opens weak
Jan 1, 1970 • timesnownews.com
Alexion’s Ultomiris Hits Mark in Phase III for Myasthenia Gravis
Jan 1, 1970 • BioSpace
AL Amyloidosis: Alexion, AstraZeneca Rare Disease, takes over Caelum Biosciences, Inc.
Jan 1, 1970 • EuropaWire.eu
AstraZeneca completes purchase of rare disease specialist Alexion Pharmaceuticals
Jan 1, 1970 • Delaware Business Now